4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0000950170-24-077944
Chief Executive Officer sold 12,930 shares at $23.10 ($298,711)
- Chief Executive Officer acquired 12,930 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kirn David Chief Executive Officer | 2024-06-24 | Option exercise 10b5-1 | +12,930 | $14.42 | $186,451 | 1,072,083 | D |
| Kirn David Chief Executive Officer | 2024-06-24 | Sale 10b5-1 | −12,930 | $23.10 | $298,711 | 1,059,153 | D |
| Derivatives | |||||||
| Kirn David Chief Executive Officer | 2024-06-24 | Option exercise · Stock Option (Right To Buy) 10b5-1 | −12,930 | 577,070 | D | ||
| Open-market sales · 12,930 sh · avg $23.10 · $298,711 | |||||||
Loading xslF345X05/ownership.xml…